# Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma

> **NCT05505461** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 26 (estimated)

## Conditions studied

- Adenocarcinoma of Esophagogastric Junction

## Interventions

- **DRUG:** neoadjuvant Radiation plus SOX and PD-1 antibody

## Key facts

- **NCT ID:** NCT05505461
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-01
- **Primary completion:** 2025-01
- **Final completion:** 2027-12
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2022-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05505461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05505461, "Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05505461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*